FDA adcomm votes in favor of Ipsen's fibrodysplasia drug
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted in support of the efficacy and risk-benefit profile of Ipsen Biopharmaceuticals’ drug palovarotene, which the agency …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
